Good outcomes of bioresorbable scaffolds in off-label cases

Original Title: Clinical outcomes following “off-label” versus “established” indication of bioresorbable scaffolds for treatment of coronary artery disease in a real-world population.

Reference: Tadashi Miyazaki, et al EuroIntervention 2016;11:475-478.

 

Courtesy of Dr. Carlos Fava.

 

Bioresorbable scaffolds (BSB) have shown their benefit in different studies, but there is little information available on “off label” indications in the real world.

The study analyzed 189 patients with 260 lesions receiving BSB; only 21 (11.1%) were “on-label” indications and 168 (88.9%) with 225 lesions were “off-label” indications. The device used was the everolimus eluting scaffold Absorb (Abbott Vascular).

Patients in the “off-label” group were more often diabetic (28.6% vs 4.8%; p=0.03), with higher SYNTAX score (16.9 vs. 11.5; p=0.01), more lesions B2/C (54.3% vs. 80%; p=0.002), longer lesions (28 mm. vs. 13 mm p=0.01) and bigger number of implanted stents (1.17 vs. 1.59; p=<0.001).

Bifurcation lesions were similar in both groups. 4.4% of rotational atherectomy was used in the “off-label” patients to prepare the lesion.

While in hospital, there were no differences in MACE combined events, with an only event in the “off label” group due to a thrombus in the scaffold two hours post procedure.

At one year, neither were there differences in target vessel revascularization or target lesion failure. Two patients “off-label” presented stent thrombosis and received emergency PCI with second generation DES.

 

Conclusion

In the real world, 88.9% of patients received BSB with an “off-label” indication. “Off-label” indication of BSB seems to be associated to an acceptable evolution considering the complexity of the analyzed group.

 

Editorial Comment

This analysis shows that BSB assessed in real world patients with complex lesions offer a very good performance compared to second generation DES.

 

Courtesy of Dr. Carlos Fava. Interventional Cardiologist. Favaloro Foundation – Buenos Aires, Argentina.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...